Skip to main content
Log in

Prämature Ovarialinsuffizienz

Premature Ovarian Insufficiency

Insuffisance Ovarienne Prématurée

  • Originalien
  • Published:
Journal für Gynäkologische Endokrinologie/Schweiz Aims and scope

Zusammenfassung

Der Begriff „prämature Ovarialinsuffizienz“ (POI) bezeichnet den vorzeitigen Verlust der Ovarialfunktion vor dem 40. Lebensjahr mit dem konsekutiven kombinierten Auftreten eines hypergonadotropen Hypogonadismus und einer primären/sekundären Amenorrhoe. Die Diagnostik beinhaltet eine detaillierte Anamnese (Chemotherapie, Radiotherapie, Operationen) sowie die Abklärung genetischer Ursachen und eines polyglandulären Autoimmunsyndroms. Bei Diagnosestellung wird die Durchführung eines DXA-Scans zur Bestimmung der Basisknochendichte empfohlen. Die prämature Ovarialinsuffizienz hat nicht nur einschneidende Auswirkungen auf die Fertilität, sondern geht auch mit negativen Langzeitfolgen u. a. auf die Knochengesundheit, das kardiovaskuläre System und die kognitive Funktion einher. Eine Hormonersatztherapie (HRT) zumindest bis zum durchschnittlichen regelrechten Menopausenalter wird zur Primärprävention östrogenmangelbedingter Langzeitfolgen empfohlen. Die Risiko-Nutzen-Analyse einer HRT, wie wir sie aus Daten von Frauen mit regelrechter Menopause kennen, darf nicht uneingeschränkt auf das Kollektiv der Patientinnen mit POI extrapoliert werden. Bei Patientinnen mit POI wiegt der Nutzen einer HRT deutlich schwerer als die potenziellen Risiken.

Résumé

Le terme »insuffisance ovarienne prématurée« désigne l’épuisement prématuré de la fonction ovarienne avant la 40e année de vie, avec développement consécutif d’un hypogonadisme hypergonadotrope associé à une aménorrhée primaire/secondaire. Le processus de diagnostic comprend une anamnèse détaillée (chimiothérapie, radiothérapie, interventions chirurgicales) ainsi que la vérification de causes génétiques et d’un éventuel syndrome polyendocrinien auto-immun. Si le diagnostic est établi, on recommande de faire un scan DXA pour déterminer la densité minérale osseuse de base. En plus de ses conséquences décisives pour la fertilité, l’insuffisance ovarienne prématurée a d’autres conséquences négatives à long terme, entre autres sur la santé des os, le système cardio-vasculaire et la fonction cognitive. Un traitement hormonal substitutif poursuivi au moins jusqu’à l’âge normal de la ménopause est recommandé pour la prévention primaire des conséquences à long terme du déficit œstrogénique. L’analyse connue du rapport avantages-risques du THS, établie d’après les données des femmes ménopausées à l’âge normal, ne peut pas être extrapolée sans restriction au collectif des patientes atteintes d’une IOP. Chez les patientes ménopausées prématurément, les avantages d’un THS prédominent nettement par rapport aux risques potentiels.

Abstract

The term “premature ovarian insufficiency” (POI) describes the premature loss of ovarian function before the age of 40 years and is accompanied by a combination of hypogonadotropic hypogonadism and primary/secondary amenorrhea. The diagnostic process includes a detailed anamnesis (chemotherapy, radiation therapy, operations) and the exclusion of genetic causes as well as polyglandular autoimmune syndrom. At diagnosis measurement of bone density is recommended. POI not only has an adverse impact on fertility but is also associated with negative long-term effects on bone health, the cardiovascular system and cognitive function. To prevent estrogen deficiency-related long-term consequences hormone replacement therapy (HRT) at least until the average natural menopause age is recommended. The benefit-risk profile of HRT in naturally postmenopausal women may not be unrestrictedly extrapolated to the collective of patients with POI. In patients with POI the benefits of HRT far outweigh the potential risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Albright F, Smith P, Fraser R (1942) A syndrome characterized by primary ovarian insufficiency and decreased stature. Am J Med Sci 204:625–648

    Article  Google Scholar 

  2. European Society for Human Reproduction and Embryology (2016) ESHRE guideline: management of women with premature ovarian insufficiency. Hum Reprod 31(5):926–937

    Article  Google Scholar 

  3. Qin Y et al (2015) Genetics of primary ovarian insufficiency: new developments and opportunities. Hum Reprod Update 21(6):787–808

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Jiao X et al (2012) Cytogenetic analysis of 531 Chinese women with premature ovarian failure. Hum Reprod 27(7):2201–2207

    Article  PubMed  CAS  Google Scholar 

  5. Kalantari H et al (2013) Cytogenetic analysis of 179 Iranian women with premature ovarian failure. Gynecol Endocrinol 29(6):588–591

    Article  PubMed  Google Scholar 

  6. Michala L et al (2008) Swyer syndrome: presentation and outcomes. BJOG 115(6):737–741

    Article  PubMed  CAS  Google Scholar 

  7. Wittenberger MD et al (2007) The FMR1 premutation and reproduction. Fertil Steril 87(3):456–465

    Article  PubMed  CAS  Google Scholar 

  8. Silva CA et al (2014) Autoimmune primary ovarian insufficiency. Autoimmun Rev 13(4–5):427–430

    Article  PubMed  CAS  Google Scholar 

  9. Hoek A, Schoemaker J, Drexhage HA (1997) Premature ovarian failure and ovarian autoimmunity. Endocr Rev 18(1):107–134

    PubMed  CAS  Google Scholar 

  10. Kim TJ et al (1997) Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 89(5 Pt 1):777–779

    Article  PubMed  CAS  Google Scholar 

  11. Howell S, Shalet S (1998) Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 27(4):927–943

    Article  PubMed  CAS  Google Scholar 

  12. Gracia CR et al (2012) Impact of cancer therapies on ovarian reserve. Fertil Steril 97(1):134–140.e1

    Article  PubMed  Google Scholar 

  13. Raffi F, Metwally M, Amer S (2012) The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 97(9):3146–3154

    Article  PubMed  CAS  Google Scholar 

  14. Coccia ME et al (2011) Ovarian surgery for bilateral endometriomas influences age at menopause. Hum Reprod 26(11):3000–3007

    Article  PubMed  Google Scholar 

  15. Visvanathan N, Wyshak G (2000) Tubal ligation, menstrual changes, and menopausal symptoms. J Womens Health Gend Based Med 9(5):521–527

    Article  PubMed  CAS  Google Scholar 

  16. Siddle N, Sarrel P, Whitehead M (1987) The effect of hysterectomy on the age at ovarian failure: identification of a subgroup of women with premature loss of ovarian function and literature review. Fertil Steril 47(1):94–100

    Article  PubMed  CAS  Google Scholar 

  17. Pokoradi AJ, Iversen L, Hannaford PC (2011) Factors associated with age of onset and type of menopause in a cohort of UK women. Am J Obstet Gynecol 205(1):34.e1–34.e13

    Article  Google Scholar 

  18. Hamoda H, British Menopause S, Women’s Health C (2017) The British Menopause Society and Women’s Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health 23(1):22–35

    Article  PubMed  Google Scholar 

  19. Roeters van Lennep JE et al (2016) Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol 23(2):178–186

    Article  PubMed  Google Scholar 

  20. Kanis JA et al (2016) A systematic review of intervention thresholds based on FRAX : a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11(1):25

    Article  PubMed  PubMed Central  Google Scholar 

  21. Popat VB et al (2009) Bone mineral density in estrogen-deficient young women. J Clin Endocrinol Metab 94(7):2277–2283

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Bachelot A et al (2009) Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. Eur J Endocrinol 161(1):179–187

    Article  PubMed  CAS  Google Scholar 

  23. Crofton PM et al (2010) Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. Clin Endocrinol (oxf) 73(6):707–714

    Article  CAS  Google Scholar 

  24. Cartwright B et al (2016) Hormone replacement therapy versus the combined oral contraceptive pill in premature ovarian failure: a randomized controlled trial of the effects on bone mineral density. J Clin Endocrinol Metab 101(9):3497–3505

    Article  PubMed  CAS  Google Scholar 

  25. van Kasteren YM, Schoemaker J (1999) Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 5(5):483–492

    Article  PubMed  Google Scholar 

  26. Rocca WA et al (2007) Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69(11):1074–1083

    Article  PubMed  CAS  Google Scholar 

  27. Phung TK et al (2010) Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord 30(1):43–50

    Article  PubMed  Google Scholar 

  28. Rocca WA, Grossardt BR, Shuster LT (2014) Oophorectomy, estrogen, and dementia: a 2014 update. Mol Cell Endocrinol 389(1–2):7–12

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Langrish JP et al (2009) Cardiovascular effects of physiological and standard sex steroid replacement regimens in premature ovarian failure. Hypertension 53(5):805–811

    Article  PubMed  CAS  Google Scholar 

  30. Mueck AO (2012) Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 15(Suppl 1):11–17

    Article  PubMed  CAS  Google Scholar 

  31. Davey DA (2013) HRT: some unresolved clinical issues in breast cancer, endometrial cancer and premature ovarian insufficiency. Womens Health (Lond) 9(1):59–67

    Article  CAS  Google Scholar 

  32. Nunnelee JD (2009) Review of an article: Canonico M, Plu-Bureau G, Lowe G, Scarabin P. (2008). Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. British Medical Journal 10(336):1227–1231. J Vasc Nurs 27(1):17

    Article  PubMed  Google Scholar 

  33. Canonico M et al (2010) Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 30(2):340–345

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Susanna Weidlinger.

Ethics declarations

Interessenkonflikt

S. Weidlinger gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weidlinger, S. Prämature Ovarialinsuffizienz. J. Gynäkol. Endokrinol. 21, 51–57 (2018). https://doi.org/10.1007/s41975-018-0045-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s41975-018-0045-1

Schlüsselwörter

Mots clés

Keywords

Navigation